|
Pharma cos engaged in R&D need to understand changes happening in the sector: Dr Shailesh Ayyangar
|
|
Peethaambaran Kunnathoor, Chennai
July 29 , 2016
|
|
|
Considering the changes happening in health and pharma sectors world
over, the pharmaceutical companies engaged in research and development
(R&D) activities in India must figure out and comprehend the
transformation and adopt measures to replicate it.
In the western
world, the R&D activities in pharmaceutical area are going through
turmoil due to regulatory hurdles and the political developments there.
Similar challenges are occurring in the field of innovation in India
also, according to Dr Shailesh Ayyangar, president of the Organisation
of Pharmaceutical Producers of India (OPPI), and the managing director
of Sanofi India Limited.
As far as Indian pharma sector is
concerned, the major pharma companies in the country are concentrated on
targeted therapies. Understanding of diseases helps for major changes
in research. India has a number of manufacturing companies to undertake
research activities for targeted therapies. The situation needs the
support of the government in large scale.
Dr Ayyangar was
delivering a lecture on the subject, “Roadmap for Marketing to Small and
Medium Pharma Companies in the Current Scenario”, at a function
organised by TN IPA and TN Pharmaceutical Welfare Trust in Chennai.
He
said though regulatory hurdles are rising up everywhere, the world is
opening up for more molecules to be off-patented, which will become
helpful for large scale researches. Manufacturers who want to engage in
R&D work must be aware of the situation and be prepared for it.
Every employee of each company should be viewed as a source for
innovation.
According to Ayyangar, India stands next to US in the
case of US FDA plants. This is a major advantage for innovation and a
facility to face challenges.
Indian pharma industry has the
potential to produce all kinds of combination drugs. Centralized
regulatory system of the country is also helpful for undertaking
research activities. A remarkable thing seems to be better than other
countries is that either the government or the people of the country are
not willing to accept low quality medicines. This always encourages for
innovation and research.
As changes happen in the research area,
changes are also occurring on the government side, patients’ side and
on the physicians’ side. Government is spending huge amount of money for
educating the public on resistance aspect of the medicines. Emergence
of ‘super power patients’ forces the government for scrutiny of
marketing practices and to control price mechanism. Besides, the new age
physicians opt for innovative products, he said adding that all the
industrial units must understand these changes happening in the pharma
sector.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|